Appendix 4E and Preliminary Financial Report 2020

CLINUVEL PHARMACEUTICALS LTD today announced its Appendix 4C – Quarterly Cashflow Report and Activity Report for the period 01 April to 30 June 2020. All figures are rounded and reported in Australian dollars. Key Highlights: •  Cash receipts $10,403,000 over the quarter •  Net cash flow of $7,175,000 •  Cash and equivalents on hand increased […]

Liebe Aktionäre, Freunde, Es stellt sich eine neue Welt dar, die darauf hinweist, dass das Virus nicht so leicht zu beseitigen sein wird. Waehrend wir es akzeptieren, einen Modus der Koexistenz zu finden, muessen wir für die mehr als 600.000 Menschen, die ihr Leben verloren haben und unzählige weitere, die von dieser Pandemie betroffen sind, […]

Communiqué IV, 2020 – 22 July 2020 Dear shareholders, friends, As a new world presents itself indicating that the virus will not easily be eliminated as we are accepting to find a modus co-existentiae, albeit we need to pause for the more than 600,000 people who have lost their lives and countless more impacted by […]

Read more…

Drug to be evaluated in patients with acute and systemic diseases Read more…

CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and conditions of issue that the following unquoted performance rights have lapsed and forfeited […] Download PDF

Download PDF with speaker notes

Liebe Aktionäre, Freunde, Die außergewöhnlichen Zeiten, in denen wir leben, haben alle Kontinente beeinflusst. Jedes verlorene Leben war eins zu viel. Ich kann unseren italienischen medizinischen Kollegen, Patienten und Familien, die mit der Tragödie kämpfen, nicht genug Empathie entgegenbringen. Das Virus hat alle Ecken der Welt befallen und Italien nicht verschont, insbesondere die Regionen Lombardei, […]

Download PDF

Dear shareholders, friends, The extraordinary times in which we are living have affected all continents. Each life lost has been one too many. I cannot express enough empathy to our Italian medical colleagues, patients and families battling it out with the tragedy. The virus has affected all corners of the world and has not spared […]

Fellow shareholders, In my March letter I wished all good health during uncertain times. It is now clear the extent of damage COVID-19 has caused and will cause for many years in the future. I want to again share my thoughts on the long-term view of CLINUVEL, and how the business was set up to […]

With thanks to Andrea Minoglio we are able to share a copy of his intimate EPP documentary Overexposed with Mandarin subtitles. What’s your life like when your skin, like an ultra-sensitive film, gets burned as soon as you expose it to the slightest amount of light? Using a series of interviews and stories, included that […]

EXECUTIVE SUMMARY CLINUVEL, FDA and global vitiligo experts attended FDA meeting on 29 April Type C Meeting followed up with further amendments to CUV104 clinical study protocol CLINUVEL PHARMACEUTICALS LTD today confirmed that it attended a Type C meeting on 29 April with the US Food and Drug Administration (FDA) and global clinical experts in […]